查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990250

胃肠道药物市场：按产品类型、给药途径和分销管道分類的全球市场预测，2026-2032年

Gastrointestinal Agents Market by Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，消化器官系统药物市场价值为631.2亿美元，预计到2026年将成长至661.5亿美元，复合年增长率为5.13%，到2032年将达到896.4亿美元。

主要市场统计数据
基准年 2025 631.2亿美元
预计年份：2026年 661.5亿美元
预测年份 2032 896.4亿美元
复合年增长率 (%) 5.13%

简要概述目前影响消化器官系统药物开发和分销的临床因素、商业性趋势和策略重点。

消化器官系统药物市场正受到多种因素的共同影响而不断发展：临床实践的改变、患者期望的提高以及科学的快速进步。本执行摘要全面概述了影响消化器官系统治疗领域产品开发、商业化和供应链管理决策的治疗领域、临床因素和商业性趋势。

科学进步、数位医疗模式、监管监督和基于价值的支付趋势如何共同作用，重塑治疗重点、商业模式和价值链策略。

消化器官系统药物领域正经历着由科学、病患期望和不断发展的医疗服务模式所驱动的变革。我们对肠道微生物组和宿主-微生物相互作用的理解不断加深，使得益生菌、益生元和标靶微生物组疗法从辅助性治疗跃升为治疗探索的核心要素。同时，精准医疗方法正将基于生物标记的治疗选择纳入到以往主要关注症状控制的讨论中。

本研究评估了美国关税政策的调整如何影响消化器官系统药物供应链中的采购决策、製造韧性和跨部门合作。

2025年的关税环境对医药原料和成品药都产生了影响，对产业相关人员而言，这是一个重要的策略转捩点。影响活性成分、辅料、包装材料和成品製​​剂的关税调整正在影响采购决策、利润率管理和采购地点。各公司正在透过重新评估供应商组合、加快二级资讯认证流程以及增加缓衝库存来应对这一变化，从而缓解采购波动。

详细的细分洞察揭示了产品类型、给药途径和分销管道的差异如何决定临床定位、配方策略和商业性执行。

市场区隔能够驱动精准的市场策略，并明确临床差异化与商业性机会的交会点。根据产品类型，市场涵盖急性症状类药物（如制酸剂和止吐药）、针对运动和分泌功能的治疗类药物（如H2受体拮抗剂和质子帮浦阻断剂）以及辅助类药物（包括泻药以及利用微生物组科学的益生元和益生菌疗法）。在制酸剂中，氢氧化铝、碳酸钙、氢氧化镁、碳酸氢钠和製剂的差异会影响製剂策略、患者耐受性考量和市场定位。止泻药大致分为吸附剂和鸦片类衍生物。吸附剂包括次水杨酸铋和高岭土果胶，而鸦片类衍生物包括地芬诺酯、阿托品和洛哌丁胺等药物，每种药物都有其独特的安全性和监管特性。根据作用机制，止吐药可进一步分为多巴胺拮抗剂、NK1受体拮抗剂和5-羟色胺受体拮抗剂。在这些类别中，甲氧氯普胺、丙氯拉Aprepitant、阿瑞吡坦、Granisetron、格拉司琼、Ondansetron和Palonosetron等特定分子影响着关于其临床定位和处方集的讨论。 H2受体拮抗剂包括西咪替丁、法莫替丁、尼扎替丁和雷尼替丁等药物，而质子帮浦阻断剂包括Esomeprazole拉唑、兰索拉唑、奥美拉唑、泮托拉唑和Rabeprazole。每个亚类都有不同的生命週期管理和病患依从性的考量。泻药可分为容积性泻药、润滑性泻药、渗透性泻药、刺激性泻药和粪便软化剂。容积性泻药包括甲基纤维素、聚卡波非和车前子，而渗透性泻药包括乳果糖、聚乙二醇和山梨醇。这种区分对于临床指导、患者咨询以及非处方药和处方药的发展趋势至关重要。益生菌和益生元包括益生元（如果寡糖和菊糖）以及益生菌菌株（如双歧桿菌、乳酸桿菌和布氏酵母菌）。这些都导致​​了菌株特异性的证据要求和监管途径。

影响美洲、欧洲、中东和非洲以及亚太地区市场准入、商业化和生产优先事项的区域战略挑战。

区域趋势持续影响企业的产品上市、供应链韧性和商业性投资的优先顺序。在美洲，支付者和医疗服务提供者日益关注疗效、成本控制和真实世界数据（REW），促使製造商加强上市后证据的收集并进行价值论证活动。北美地区的医院采购流程和专科药房管道正在影响医院管理和专科消化器官系统疗法的应用模式。同时，拉丁美洲的趋势要求企业采取适应性定价策略并建立区域製造伙伴关係，以应对准入限制。

製药公司为加强其产品线而采取的企业策略和战术性措施，最大限度地延长了消化器官系统药物的产品生命週期并优化了分销。

胃肠道治疗领域的公司正在采取多种策略倡议，以维持成长、确保获利并提供差异化的临床价值。拥有成熟产品系列的公司正投资于生命週期管理策略，例如开发新製剂、固定剂量组合药物和拓展适应症，以在竞争激烈的治疗领域中保持领先地位。同时，其他公司则致力于加大研发投入，探索以微生物组为基础的方法、新型受体标靶和治疗平台，以满足慢性胃肠道疾病领域尚未满足的医疗需求。

建议製药公司采取切实可行的跨部门倡议，将证据商业化和供应弹性相结合，以扩大患者用药范围并实现竞争差异化。

行业领导企业应优先考虑制定协调一致的议程，将临床证据的获取与切实可行的商业性执行和稳健的业务运营相结合。首先，应在研发计划早期整合基于机制的证据和真实世界数据（RWE）项目，以支持差异化主张并促进与支付方的对话。投资于生物标记主导的临床试验和患者报告结局的纵向研究将增强价值提案。其次，应实现原料药和原料药筹资策略的多元化，并对替代生产合作伙伴进行认证，以降低区域贸易中断带来的风险。此外，应儘早与监管回应团队接洽，以简化与生产变更相关的必要申请程序。

调查方法解释如何透过质性访谈、监管审查和主题综合分析，得出实用见解，避免投机性的市场预测。

本摘要所依据的研究融合了第一手和第二手调查方法，旨在建构全面平衡的观点。透过对临床医生、处方集决策者、采购经理和行业高管的定性访谈，我们深入了解了产品应用驱动因素、供应考量以及支付方趋势。这些访谈内容与监管指南、临床文献和产品技术资讯进行了交叉核对，以确保临床和营运方面的准确性。

简明结论指出，临床证据、商业策略和营运准备是决定胃肠道药物产品成功实施的关键因素。

总而言之，消化器官系统药物市场格局正处于转折点，随着科学创新、分销管道的演变和供应韧性的交汇，策略挑战也不断重塑。能够将治疗差异化与可靠的实证医学证据、灵活的筹资策略以及针对特定管道的商业模式相结合的公司，将更有利于满足监管机构的审查和支付方的期望。跨部门合作以及将真实世界数据（REW）儘早整合到研发计划中，将加速产品推广应用，并促进与医疗系统和支付方之间的价值对话。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：胃肠道药物市场：依产品类型划分

  • 制酸剂
    • 氢氧化铝
    • 碳酸钙
    • 组合配方
    • 氢氧化镁
    • 碳酸氢钠
  • 止泻
    • 吸附剂
      • 次水杨酸铋
      • 高岭土/果胶
    • 鸦片类衍生物
      • 地芬诺酯阿托品
      • 洛哌丁胺
  • 止吐药
    • 多巴胺拮抗剂
      • 甲氧氯普胺
      • 丙氯拉嗪
    • NK1受体拮抗剂
      • Aprepitant
      • 福沙普利坦
    • 血清素受体拮抗剂
      • Granisetron
      • Ondansetron
      • Palonosetron
  • H2受体拮抗剂
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 泻药
    • 容积性泻药
      • 甲基纤维素
      • 聚卡波非
      • 萤光棒
    • 润滑剂
    • 渗透压
      • 乳果糖
      • 聚乙二醇
      • 山梨醇
    • 刺激性泻药
    • 软便剂
  • 益生菌和益生元
    • 益生元
      • 果寡糖
      • 菊糖
    • 益生菌
      • 双歧桿菌
      • 乳酸桿菌
      • 布拉氏酵母
  • 质子帮浦阻断剂
    • Esomeprazole
    • 兰索拉唑
    • 奥美拉唑
    • 泮托拉唑
    • Rabeprazole

第九章：胃肠道药物市场：依给药途径划分

  • 肌肉内部
  • 静脉
    • 博拉斯注射
    • 静脉注射
  • 口服
    • 胶囊
    • 液态糖浆
    • 粉末
    • 药片
  • 外用
    • 奶油
    • 凝胶
    • 栓剂

第十章：胃肠道药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：胃肠道药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：胃肠道药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：胃肠道药物市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国胃肠道药物市场

第十五章：中国胃肠药物市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • American Health
  • Amway Corporation
  • Archer-Daniels-Midland Company
  • ARKOPHARMA Laboratories, Company Limited
  • Bayer AG
  • Biomedical Research Laboratories, LLC
  • DuPont de Nemours, Inc.
  • Dymatize Enterprises LLC
  • FANCL Corporation
  • Glanbia PLC
  • GlaxoSmithKline PLC
  • Herbalife Nutrition Ltd.
  • Himalaya Wellness Company
  • Nature's Sunshine Products, Inc.
  • Nestle SA
  • Nutraceutical International Corporation
  • NutraScience Labs
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Pragati Biocare Pvt. Ltd.,
  • Procter & Gamble Health Limited
  • Pure Encapsulations, LLC.
  • Sabinsa Corporation
  • Sanofi SA
Product Code: MRR-CB04E056533F

The Gastrointestinal Agents Market was valued at USD 63.12 billion in 2025 and is projected to grow to USD 66.15 billion in 2026, with a CAGR of 5.13%, reaching USD 89.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 63.12 billion
Estimated Year [2026] USD 66.15 billion
Forecast Year [2032] USD 89.64 billion
CAGR (%) 5.13%

A concise orienting narrative introducing the current clinical drivers commercial dynamics and strategic priorities shaping gastrointestinal agent development and distribution

The pharmaceutical landscape for gastrointestinal agents is evolving under the combined pressures of changing clinical practice, heightened patient expectations, and rapid scientific progress. This executive summary provides an integrated view of the therapeutic classes, clinical drivers, and commercial dynamics that influence decision making for product development, commercialization, and supply chain management within the GI therapeutic area.

Leading therapeutic categories span acute symptom relief through to long-term management of chronic conditions, and each category has distinct clinical profiles, patient adherence patterns, and regulatory considerations. Stakeholders face the dual challenge of optimizing value for payers and patients while sustaining robust pipelines through targeted innovation. By synthesizing clinical trends, distribution shifts, and regulatory signals, this introduction sets the scene for deeper analysis that follows and prepares readers to interpret strategic recommendations in context.

How scientific advances digital care models regulatory scrutiny and value based payment trends are jointly reshaping therapeutic priorities commercial models and supply chain strategies

The gastrointestinal agents sector is experiencing transformative shifts driven by science, patient expectations, and the evolving healthcare delivery model. Advances in our understanding of the gut microbiome and host-microbe interactions have elevated probiotics, prebiotics, and targeted microbiome therapeutics from niche adjuncts to central elements of therapeutic exploration. Meanwhile, precision medicine approaches are bringing biomarker-guided treatment selection into conversations that previously focused primarily on symptom control.

Concurrently, digital health tools and remote care pathways have reshaped how patients access therapy, adhere to regimens, and report outcomes, prompting manufacturers to integrate digital companion offerings and real-world evidence generation into launch plans. Regulatory attention on long-term safety profiles-particularly for widely used drug classes-has prompted manufacturers to invest in lifecycle management, comparative effectiveness studies, and clinician education initiatives. Supply chain resilience has emerged as a strategic priority, with companies diversifying active pharmaceutical ingredient sourcing and adopting manufacturing redundancy to mitigate disruptions.

Finally, payer emphasis on value and outcomes is accelerating adoption of value-based contracting and indication-specific pricing considerations. Collectively, these shifts converge to favor companies that combine therapeutic innovation with pragmatic commercial models, evidence generation, and agile operations, enabling them to respond to clinician preferences and evolving reimbursement pathways.

Assessing how adjustments in US tariff policy have reshaped sourcing decisions manufacturing resilience and cross functional collaboration across gastrointestinal therapeutic supply chains

The 2025 tariff environment affecting pharmaceutical inputs and finished products has introduced a notable strategic inflection point for industry participants. Tariff adjustments that touch active pharmaceutical ingredients, excipients, packaging components, and finished formulations have influenced procurement decisions, margin management, and sourcing footprints. Companies have responded by reassessing supplier portfolios, accelerating qualification of secondary sources, and increasing buffer inventories to smooth procurement volatility.

Operationally, manufacturers have expanded localization strategies where possible and have diversified contract manufacturing partners to reduce single-point dependencies. These approaches have implications for lead times, quality assurance, and regulatory filings, as establishing new manufacturing relationships often requires additional validation and regulatory engagement. In parallel, procurement teams have renegotiated commercial terms and explored hedging strategies to mitigate input cost swings, while commercial teams have engaged payers and distributors to discuss contract adjustments and shared risk models.

From a clinical supply perspective, the tariff context has elevated the importance of robust demand forecasting and integrated supply-chain planning, particularly for critical hospital-administered therapies and intravenous formulations. Regulatory affairs and quality teams have become more actively involved in sourcing decisions to ensure compliance with product registrations and to manage any changes in manufacturing sites or component provenance. Overall, the tariff landscape has reinforced the need for cross-functional collaboration across sourcing, regulatory, manufacturing, and commercial teams to preserve continuity of care and to protect therapeutic access.

Deep segmentation insight revealing how product type administration route and distribution channel distinctions determine clinical positioning formulation strategy and commercial execution

Segmentation drives targeted strategy and clarifies where clinical differentiation and commercial opportunity intersect. Based on product type, the market spans acute symptom categories such as antacids and anti-emetics, therapeutic classes addressing motility and secretion such as H2 receptor antagonists and proton pump inhibitors, and supportive categories including laxatives alongside prebiotic and probiotic approaches that leverage microbiome science. Within antacids, distinctions between aluminum hydroxide, calcium carbonate, magnesium hydroxide, sodium bicarbonate and combination formulations influence formulation strategy, patient tolerability considerations, and over-the-counter positioning. Anti-diarrheals differentiate into adsorbents and opioid derivatives, with adsorbents encompassing bismuth subsalicylate and kaolin pectin and opioid derivatives represented by agents such as diphenoxylate-atropine and loperamide, each presenting unique safety and regulatory profiles. Anti-emetics are further segmented by mechanism into dopamine antagonists, NK1 receptor antagonists and serotonin receptor antagonists, and within these groups specific molecules like metoclopramide, prochlorperazine, aprepitant, fosaprepitant, granisetron, ondansetron and palonosetron shape clinical positioning and formulary conversations. H2 receptor antagonists include agents such as cimetidine, famotidine, nizatidine and ranitidine, and proton pump inhibitors span esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole, with each subclass presenting distinct lifecycle management and patient adherence considerations. Laxatives subdivide into bulk forming, lubricant, osmotic, stimulant and stool softeners, with bulk forming options such as methylcellulose, polycarbophil and psyllium and osmotic options including lactulose, polyethylene glycol and sorbitol; these distinctions matter for clinical guidance, patient counseling and OTC versus prescription dynamics. Probiotics and prebiotics encompass prebiotics like fructooligosaccharides and inulin alongside probiotic strains including bifidobacterium, lactobacillus and saccharomyces boulardii, which introduce strain-specific evidence requirements and regulatory pathways.

Based on route of administration, differentiation across intramuscular, intravenous, oral and topical routes impacts clinical adoption, formulary placement, and manufacturing complexity. Intravenous therapies require attention to bolus injection and infusion formats, while oral dosage forms such as capsules, liquid syrups, powders and tablets demand varied stability and palatability considerations, and topical options including creams, gels and suppositories have unique patient acceptability and dispensing implications. Distribution channels further shape commercialization approaches, with hospital pharmacy dynamics differing from retail pharmacy and online pharmacy ecosystems in terms of procurement cycles, reimbursement mechanisms and stakeholder engagement. Taken together, segmentation clarifies where clinical evidence, formulation investment and commercial strategy should align to capture therapeutic demand and to manage lifecycle priorities effectively.

Regional strategic imperatives across the Americas Europe Middle East & Africa and Asia Pacific that influence access commercialization and manufacturing priorities

Regional dynamics continue to shape how companies prioritize launches, supply resilience, and commercial investments. In the Americas, payers and providers emphasize outcomes, cost containment and real-world evidence, prompting manufacturers to strengthen post-launch evidence generation and to engage in value demonstration activities. North American hospital procurement processes and specialty pharmacy channels influence adoption patterns for hospital-administered and specialty GI therapies, while Latin American dynamics require adaptive pricing strategies and regional manufacturing partnerships to address access constraints.

Europe, Middle East & Africa present a mosaic of regulatory environments and payer structures that necessitate differentiated market entry playbooks. In several European markets, rigorous health technology assessment processes favor therapies with demonstrable comparative effectiveness and cost-utility evidence, while Middle Eastern markets often prioritize rapid access pathways paired with local registration requirements. African markets pose infrastructure and distribution challenges but also opportunities for strategic partnerships that expand access to essential symptomatic therapies and probiotics.

Asia-Pacific demonstrates a heterogeneous mix of mature markets with advanced regulatory frameworks and emerging markets with significant growth in healthcare access. Regional manufacturing capacity in Asia supports a large portion of global API and formulation output, which in turn affects sourcing strategies for global manufacturers. Patient preferences, regulatory timelines, and distribution models in Asia-Pacific require nuanced engagement strategies, including local clinical collaborations and culturally tailored patient support programs to optimize uptake and adherence.

Corporate strategies and tactical maneuvers adopted by manufacturers to strengthen pipelines maximize product lifecycles and optimize distribution in gastrointestinal therapeutics

Companies across the gastrointestinal therapeutic area are pursuing multiple strategic pathways to sustain growth, protect margins, and deliver differentiated clinical value. Firms with established portfolios are investing in lifecycle management strategies such as new formulations, fixed-dose combinations, and indication expansions to maintain relevance in competitive therapeutic classes. Others are pursuing targeted R&D investments in microbiome-based approaches, novel receptor targets, and therapeutic platforms that address unmet needs in chronic GI disorders.

Strategic alliances and selective in-licensing deals have become prevalent as companies seek to accelerate pipeline diversification without bearing full discovery risk. Contract manufacturing and strategic sourcing partnerships provide scalability while enabling firms to focus internal resources on core competencies such as clinical development and market access. Commercially, manufacturers are refining distribution strategies to balance hospital, retail and online pharmacy channels, deploying channel-specific support programs and digital engagement tools to improve patient adherence and clinician awareness.

Furthermore, companies are enhancing their evidence ecosystems by integrating real-world data collection, patient-reported outcome measures, and pragmatic trial designs into development plans to support payer conversations and to inform guideline updates. Operational excellence initiatives that strengthen quality systems, regulatory readiness and supply-chain visibility remain core to sustaining trust among providers and payers, particularly when therapeutic switching or supply reallocation becomes necessary.

Actionable cross functional initiatives recommended for manufacturers to integrate evidence commercialization and supply resilience to advance patient access and competitive differentiation

Industry leaders should prioritize a coordinated agenda that aligns clinical evidence generation with pragmatic commercial execution and resilient operations. First, integrate mechanistic and real-world evidence programs early in development plans to support differentiated claims and to facilitate payer dialogues; investing in biomarker-driven trials and longitudinal patient-reported outcomes will strengthen value propositions. Second, diversify sourcing strategies for APIs and excipients and qualify alternate manufacturing partners to reduce exposure to regional trade disruptions; include regulatory teams early to streamline any required filings associated with manufacturing changes.

Third, tailor distribution strategies to account for channel-specific behaviors: design hospital engagement plans that emphasize formulary and procurement alignment, craft retail pharmacy initiatives to support OTC and chronic care adherence, and develop digital-first approaches for online pharmacy partnerships that enhance patient convenience and retention. Fourth, adopt modular commercial models that incorporate patient support programs, digital adherence tools, and outcome-based contracting pilots where appropriate to align incentives with payers and providers. Finally, foster cross-functional governance that brings R&D, regulatory, manufacturing, and commercial leadership together under a common roadmap to accelerate decision making and to ensure operational readiness for launches and supply shifts.

Methodological approach explaining how qualitative interviews regulatory review and thematic synthesis produced action oriented insights while avoiding speculative market projections

The research underpinning this summary synthesizes primary and secondary methodologies to build a comprehensive and balanced perspective. Qualitative interviews with clinicians, formulary decision makers, procurement leads and industry executives provided directional insight into adoption drivers, supply considerations and payer dynamics. These interviews were triangulated with regulatory guidance, clinical literature, and technical product information to ensure clinical and operational accuracy.

Analytical processes emphasized thematic synthesis rather than quantitative extrapolation, focusing on decision-relevant findings such as formulation tolerability, route-specific adoption patterns, distribution channel nuances, and strategic sourcing implications. Cross-validation steps included internal expert review and scenario analysis to stress-test assumptions about supply vulnerabilities and commercialization approaches. The methodology deliberately prioritized actionable insight generation and practical recommendations while avoiding speculative market sizing, ensuring that conclusions remain evidence-based and relevant for commercial and clinical stakeholders.

Concise concluding perspective that synthesizes clinical evidence commercial strategy and operational readiness as determinants of successful gastrointestinal product execution

In summary, the gastrointestinal agents landscape is at an inflection point where scientific innovation, distribution evolution and supply resilience converge to redefine strategic imperatives. Companies that align therapeutic differentiation with robust evidence generation, agile sourcing strategies, and channel-specific commercial models will be best positioned to navigate regulatory scrutiny and payer expectations. Cross-functional collaboration and early integration of real-world evidence into development plans will accelerate adoption and support value conversations with health systems and payers.

Operational readiness, particularly in manufacturing and procurement, remains essential to mitigate risks introduced by shifting trade policies and to protect continuity of care. Ultimately, pragmatic execution that translates clinical promise into accessible, affordable therapies will determine success across therapeutic classes and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Agents Market, by Product Type

  • 8.1. Antacids
    • 8.1.1. Aluminum Hydroxide
    • 8.1.2. Calcium Carbonate
    • 8.1.3. Combination Formulations
    • 8.1.4. Magnesium Hydroxide
    • 8.1.5. Sodium Bicarbonate
  • 8.2. Anti Diarrheals
    • 8.2.1. Adsorbents
      • 8.2.1.1. Bismuth Subsalicylate
      • 8.2.1.2. Kaolin Pectin
    • 8.2.2. Opioid Derivatives
      • 8.2.2.1. Diphenoxylate Atropine
      • 8.2.2.2. Loperamide
  • 8.3. Anti Emetics
    • 8.3.1. Dopamine Antagonists
      • 8.3.1.1. Metoclopramide
      • 8.3.1.2. Prochlorperazine
    • 8.3.2. NK1 Receptor Antagonists
      • 8.3.2.1. Aprepitant
      • 8.3.2.2. Fosaprepitant
    • 8.3.3. Serotonin Receptor Antagonists
      • 8.3.3.1. Granisetron
      • 8.3.3.2. Ondansetron
      • 8.3.3.3. Palonosetron
  • 8.4. H2 Receptor Antagonists
    • 8.4.1. Cimetidine
    • 8.4.2. Famotidine
    • 8.4.3. Nizatidine
    • 8.4.4. Ranitidine
  • 8.5. Laxatives
    • 8.5.1. Bulk Forming
      • 8.5.1.1. Methylcellulose
      • 8.5.1.2. Polycarbophil
      • 8.5.1.3. Psyllium
    • 8.5.2. Lubricant
    • 8.5.3. Osmotic
      • 8.5.3.1. Lactulose
      • 8.5.3.2. Polyethylene Glycol
      • 8.5.3.3. Sorbitol
    • 8.5.4. Stimulant
    • 8.5.5. Stool Softeners
  • 8.6. Probiotics & Prebiotics
    • 8.6.1. Prebiotics
      • 8.6.1.1. Fructooligosaccharides
      • 8.6.1.2. Inulin
    • 8.6.2. Probiotics
      • 8.6.2.1. Bifidobacterium
      • 8.6.2.2. Lactobacillus
      • 8.6.2.3. Saccharomyces Boulardii
  • 8.7. Proton Pump Inhibitors
    • 8.7.1. Esomeprazole
    • 8.7.2. Lansoprazole
    • 8.7.3. Omeprazole
    • 8.7.4. Pantoprazole
    • 8.7.5. Rabeprazole

9. Gastrointestinal Agents Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
    • 9.2.1. Bolus Injection
    • 9.2.2. Infusion
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Liquid Syrup
    • 9.3.3. Powder
    • 9.3.4. Tablet
  • 9.4. Topical
    • 9.4.1. Creams
    • 9.4.2. Gels
    • 9.4.3. Suppositories

10. Gastrointestinal Agents Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Gastrointestinal Agents Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gastrointestinal Agents Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gastrointestinal Agents Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gastrointestinal Agents Market

15. China Gastrointestinal Agents Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. American Health
  • 16.7. Amway Corporation
  • 16.8. Archer-Daniels-Midland Company
  • 16.9. ARKOPHARMA Laboratories, Company Limited
  • 16.10. Bayer AG
  • 16.11. Biomedical Research Laboratories, LLC
  • 16.12. DuPont de Nemours, Inc.
  • 16.13. Dymatize Enterprises LLC
  • 16.14. FANCL Corporation
  • 16.15. Glanbia PLC
  • 16.16. GlaxoSmithKline PLC
  • 16.17. Herbalife Nutrition Ltd.
  • 16.18. Himalaya Wellness Company
  • 16.19. Nature's Sunshine Products, Inc.
  • 16.20. Nestle S.A
  • 16.21. Nutraceutical International Corporation
  • 16.22. NutraScience Labs
  • 16.23. Otsuka Holdings Co. Ltd.
  • 16.24. Pfizer Inc.
  • 16.25. Pragati Biocare Pvt. Ltd.,
  • 16.26. Procter & Gamble Health Limited
  • 16.27. Pure Encapsulations, LLC.
  • 16.28. Sabinsa Corporation
  • 16.29. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 278. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 292. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 294. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 296. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 298. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 300. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 304. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINA